Last reviewed · How we verify

NCT03264040: BioMannosido

Biomarker for Mannosidosis Disease (BioMannosidosis)

Withdrawn Last updated 13 February 2023
What this trial tests

trial in Alpha-Mannosidase B Deficiency. Withdrawn.

Timeline
20 August 2018
Primary endpoint
28 February 2021
28 February 2021

Quick facts

Lead sponsorCENTOGENE GmbH Rostock
StatusWithdrawn
Study typeOBSERVATIONAL
Start date20 August 2018
Primary completion28 February 2021
Estimated completion28 February 2021
Sites3 locations across Sri Lanka, Germany, India

Conditions studied

Sponsor

CENTOGENE GmbH Rostock

Who can join

2 Months and older, any sex, with Alpha-Mannosidase B Deficiency or Lysosomal Alpha B Mannosidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Development of a new MS-based biomarker for the early and sensitive diagnosis of Mannosidosis disease from blood (plasma)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other CENTOGENE GmbH Rostock trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03264040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing